Established in 1993 as the Centre for Developmental Cancer Therapeutics (CDCT), Cancer Trials Australia continues to offer sponsors and investigators a single point of contact to manage all aspects of a clinical trial, from feasibility through to trial completion.

In addition to its clinical trial management services, CTA has been involved in a number of significant initiatives since its inception. In 2005, CTA was pivotal in implementing the Mutual Acceptance Program (MAP) across our members which allowed a trial, previously approved at one CTA site, to be recognised by other CTA sites.

In 2006, CTA funded a project to drive the development of a standard clinical trial agreement template for sponsored trials, now known as the Medicines Australia Standard Clinical Trial Agreement template. This template was endorsed by Medicines Australia in 2007, before being placed on the VMIA and Victorian Department of Human Services (DHS) websites.

Also in 2006, CTA drove the development of a First Time in Human (FTIH) protocol to enable Human Research Ethics Committees (HRECs) to strengthen their capacity to review early phase research, in particular FTIH research.

CTA continues to be involved the areas of ongoing regulatory reform and changes across the health sector, both at a Federal and State level. Our members are now supported through CTA’s strong advocacy position within Government and other peak bodies.